Equillium, Inc. - Common Stock (NQ:EQ)

1.230 -0.040 (-3.15%)

Delayed Quote Updated: 4:00 PM EDT, Oct 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Equillium, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Nano-Cap Equillium Shares Fall After Patchy Hair Loss Study Data ↗

June 04, 2024

Equillium released topline data from its Phase 2 study of EQ101 in adult patients with alopecia areata, a disease that results in patchy hair loss.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

June 04, 2024

Via Benzinga

Gold Down 1%; Bath & Body Works Shares Tumble After Q1 Results ↗

June 04, 2024

Via Benzinga

US Stocks Lower; Donaldson Earnings Beat Views ↗

June 04, 2024

Via Benzinga

Topics Earnings

Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areata

June 04, 2024

From Equillium Inc.

Via Business Wire

Equillium: Q4 Earnings Insights ↗

March 25, 2024

Via Benzinga

Equillium to Present at the Jefferies Global Healthcare Conference

May 29, 2024

From Equillium, Inc.

Via Business Wire

Equillium Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease

May 14, 2024

From Equillium, Inc.

Via Business Wire

EQ Stock Earnings: Equillium Beats EPS, Beats Revenue for Q1 2024 ↗

May 09, 2024

EQ stock results show that Equillium beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

Equillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights

May 09, 2024

From Equillium Inc.

Via Business Wire

Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists

May 07, 2024

From Equillium, Inc.

Via Business Wire

Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

April 03, 2024

From Equillium, Inc.

Via Business Wire

Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis

April 01, 2024

From Equillium, Inc.

Via Business Wire

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

March 26, 2024

Via Benzinga

EQ Stock Earnings: Equillium Beats EPS, Beats Revenue for Q4 2023 ↗

March 25, 2024

EQ stock results show that Equillium beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.

Via InvestorPlace

Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights

March 25, 2024

From Equillium, Inc.

Via Business Wire

Why Westport Fuel Systems Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

March 26, 2024

Shares of Westport Fuel Systems Inc. (NASDAQ: WPRT) fell sharply during Tuesday’s session after posting a wider-than-expected fourth-quarter loss. Westport Fuel Systems posted a quarter loss of 81...

Via Benzinga

Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference

March 22, 2024

From Equillium, Inc.

Via Business Wire

5 Stocks That More Than Doubled In February ↗

March 03, 2024

U.S. stocks rallied in February, with the S&P 500 and the Nasdaq Composite Index recording the best month in nearly a decade. Meanwhile, the Dow

Via Talk Markets

Topics Stocks

12 Health Care Stocks Moving In Monday's Intraday Session ↗

February 19, 2024

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

February 16, 2024

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

February 06, 2024

Via Benzinga

Cognizant Technology Solutions To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

December 26, 2023

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease

December 21, 2023

From Equillium, Inc.

Via Business Wire

Equillium Presents Positive Data from Phase 1b EQUALISE Study at the 2023 Annual Meeting of the American College of Rheumatology

November 13, 2023

From Equillium, Inc.

Via Business Wire

Equillium Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates

November 08, 2023

From Equillium, Inc.

Via Business Wire

Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology

November 06, 2023

From Equillium, Inc.

Via Business Wire

10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis

October 23, 2023

Via ACCESSWIRE

Equillium Announces Abstracts Accepted for Presentation at the 2023 Annual Meetings of the American Society of Nephrology and the American College of Rheumatology

October 19, 2023

From Equillium

Via Business Wire

Equillium Announces Preclinical Data from New Orally Deliverable Multi-Cytokine Inhibitor in Presentation at the 18th Annual Peptide Therapeutics Symposium

October 16, 2023

From Equillium Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.